Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

News release details

Blueprint Medicines, a leader in discovering and developing kinase drugs to treat patients with genetically defined diseases, today announced that Jeffrey Albers, Chief Executive Officer, will present a company overview at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 9:30 a.m. PST at the Westin St. Francis Hotel in San Francisco, CA.

January 8, 2015 at 12:11 AM EST